TSBX Stock Forecast 2025-2026
Distance to TSBX Price Targets
TSBX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Turnstone Biologics (TSBX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on TSBX and similar high-potential opportunities.
Latest TSBX Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, TSBX has a neutral consensus with a median price target of $0.70 (ranging from $0.40 to $1.00). Currently trading at $0.37, the median forecast implies a 88.2% upside. This outlook is supported by 0 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TSBX Analyst Ratings
TSBX Price Target Range
Latest TSBX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TSBX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 14, 2024 | B of A Securities | Charlie Yang | Neutral | Downgrade | $0.50 |
| Aug 19, 2024 | B of A Securities | Geoff Meacham | Buy | Maintains | $10.00 |
| Aug 19, 2024 | Piper Sandler | Joseph Catanzaro | Overweight | Maintains | $3.75 |
| Aug 15, 2023 | B of A Securities | Geoff Meacham | Buy | Initiates | $18.00 |
| Aug 15, 2023 | Piper Sandler | Joseph Catanzaro | Overweight | Initiates | $20.00 |
Turnstone Biologics Corp (TSBX) Competitors
The following stocks are similar to Turnstone Biologics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Turnstone Biologics Corp (TSBX) Financial Data
Turnstone Biologics Corp has a market capitalization of $8.60M with a P/E ratio of -0.1x. The company generates $19.31M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -305.8% and return on equity of -94.5%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Turnstone Biologics Corp (TSBX) Business Model
About Turnstone Biologics Corp
Develops innovative immunotherapies for cancer.
Turnstone Biologics generates revenue through the research and development of novel oncolytic virus therapies. These therapies are designed to stimulate the immune system to fight cancer, and the company aims to advance multiple clinical and preclinical programs that target various tumor types, potentially leading to lucrative partnerships or licensing agreements with larger pharmaceutical firms.
The company is positioned within the rapidly evolving oncology sector, focusing on pioneering therapeutic modalities that differ from traditional cancer treatments. This unique approach not only aims to enhance patient outcomes but also holds the potential to significantly impact the healthcare and pharmaceutical industries.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
81
CEO
Dr. Sammy J. Farah M.B.A., Ph.D.
Country
United States
IPO Year
N/A
Website
turnstonebio.comTurnstone Biologics Corp (TSBX) Latest News & Analysis
Turnstone Biologics Corp. (TSBX) has received a Zacks Rank #2 (Buy) upgrade, indicating improved earnings prospects and potential for stock price increase.
Turnstone Biologics' upgrade to Zacks Rank #2 indicates improved earnings outlook, likely boosting investor confidence and driving the stock price higher.
Turnstone Biologics is advancing its Selected TIL technology for solid tumors, with Phase 1 trials ongoing for TIDAL-01. Preclinical data will be presented at the SITC Annual Meeting, Nov 6-10, 2024.
Turnstone's advancements in TIL technology and ongoing Phase 1 trials could enhance treatment options for solid tumors, potentially increasing the company's market value and investor interest.
Turnstone Biologics (NASDAQ: TSBX) shares are declining after the company reported a diluted earnings per share of -92 cents in its latest earnings report.
Turnstone Biologics' significant loss in earnings per share signals financial struggles, potentially leading to reduced investor confidence and impacting stock performance.
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
7 months agoTurnstone Biologics reported positive Phase 1 trial data for TIDAL-01 in metastatic colorectal cancer, with one complete response. The company's cash is projected to support operations through Q3 2025.
Positive Phase 1 trial results for a cancer treatment and a strong cash position until 2025 suggest potential growth and stability for Turnstone Biologics, influencing investor confidence.
Turnstone Biologics Corp. (TSBX) shares fell following the release of initial data from its Phase 1 STARLING trial for TIDAL-01 in metastatic microsatellite-stable colorectal cancer.
TSBX's stock decline indicates investor concern over the initial trial data, which could impact the company's future prospects and funding opportunities in oncology.
Turnstone Biologics reported positive initial data from its Phase 1 STARLING trial of TIDAL-01 in advanced colorectal cancer, showing a 25% overall response rate and 50% disease control rate.
Positive early trial results for Turnstone's TIDAL-01 in advanced colorectal cancer may boost investor confidence, indicating potential market value and growth in the biotech sector.
Frequently Asked Questions About TSBX Stock
What is Turnstone Biologics Corp's (TSBX) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Turnstone Biologics Corp (TSBX) has a median price target of $0.70. The highest price target is $1.00 and the lowest is $0.40.
Is TSBX stock a good investment in 2025?
According to current analyst ratings, TSBX has 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.37. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TSBX stock?
Wall Street analysts predict TSBX stock could reach $0.70 in the next 12 months. This represents a 88.2% increase from the current price of $0.37. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Turnstone Biologics Corp's business model?
Turnstone Biologics generates revenue through the research and development of novel oncolytic virus therapies. These therapies are designed to stimulate the immune system to fight cancer, and the company aims to advance multiple clinical and preclinical programs that target various tumor types, potentially leading to lucrative partnerships or licensing agreements with larger pharmaceutical firms.
What is the highest forecasted price for TSBX Turnstone Biologics Corp?
The highest price target for TSBX is $1.00 from at , which represents a 168.8% increase from the current price of $0.37.
What is the lowest forecasted price for TSBX Turnstone Biologics Corp?
The lowest price target for TSBX is $0.40 from at , which represents a 7.5% increase from the current price of $0.37.
What is the overall TSBX consensus from analysts for Turnstone Biologics Corp?
The overall analyst consensus for TSBX is neutral. Out of 3 Wall Street analysts, 0 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $0.70.
How accurate are TSBX stock price projections?
Stock price projections, including those for Turnstone Biologics Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
